Nanomedicine Market Size, Share, Opportunities, And Trends By Application (Drug Delivery, Regenerative Medicine, Diagnostic Imaging, Cancer Treatment, Infectious Disease Treatment, Others), By Technology (Machine Learning, Deep Learning, Natural Language Processing (NLP), Other AI Technologies), By Product (Nanoparticles, Nanoparticles Therapeutics, Nanosensors, Nanodevices, Others), By End-User (Hospitals and Clinics, Research Institutes and Laboratories, Pharmaceutical Companies, Others), And By Geography - Forecasts From 2023 To 2028

The Nanomedicine Market was valued at US$221.12 billion in 2021.

The medical application of nanotechnology is the focus of the interdisciplinary field of nanomedicine. Nanoscale materials and technologies for disease diagnosis, treatment, and prevention are the subjects of this research. Nanoparticles, nanocarriers, and nanostructures enable targeted medication delivery, imaging, and diagnostics. The fields of personalized medicine, regenerative medicine, and cancer treatment could all be completely transformed by nanomedicine. The nanomedicine market size is still developing, with ongoing research and development aimed at increasing nanomedicine products' efficacy, safety, and scalability.

Introduction:

The demand for better healthcare solutions, the rising incidence of chronic diseases, and advancements in nanotechnology have all contributed to the significant expansion of the nanomedicine market growth in recent years. The market includes segments such as therapeutics, diagnostics, regenerative medicine, and drug delivery systems. The purpose of disease diagnosis, treatment, and prevention, entails the design, growth, development, and application of nanoscale materials and technologies.

Key Players in the Nanomedicine Market:

• Abbott Laboratories: Nanomaterials, diagnostics, and medical equipment are the primary areas of focus at Abbott Laboratories.
• Amgen Inc.: They center around natural medications and are investigating nanomedicine for designated drug conveyance.
• Gilead Sciences, Inc. and Johnson & Johnson: They investigate nanomedicine for antiviral medications and regenerative medicine.
• GE Healthcare: They use nanotechnology to provide imaging and diagnostic solutions.
• Merck and Co., Inc.: They reserve nanomedicine research for medicine conveyance and designated treatment.

Drives:

• Increasing prevalence of chronic diseases:

The expanding field of nanomedicine offers potential solutions to the worldwide rise in chronic diseases. Chronic diseases are becoming more common as a result of changes in lifestyle, and an aging population. Nanotechnology may be used by organizations and researchers to develop ground-breaking medicines that enhance the quality of life and management of chronic diseases. The World Health Organization predicts a significant increase in the prevalence of chronic diseases, making nanomedicine an essential component of improved health outcomes.

• Advancements in nanotechnology:

New materials, devices, and processes with transformative potential in healthcare were developed thanks to nanoscale material modification. Dendrimers, nanoparticles, and liposomes improve medication delivery, enabling more targeted treatment and better outcomes. Biosensors and imaging agents at the nanoscale improve disease detection and monitoring, enabling earlier diagnosis. Nanomaterial progress can change medical services by giving more exact treatments and precise diagnostics.

• Enhanced diagnostics capabilities:

Advancements in nanotechnology will bolster enhanced diagnostic capabilities, precision medicine, and healthcare delivery. Because of their high selectivity and sensitivity, nanoscale biosensors and probes make it possible to precisely monitor targeted compounds and early illness detection. Nanotechnology-based diagnostics are more sensitive to identifying infections, cancer biomarkers, and genetic mutations. In situations where resources are limited, portable and point-of-care diagnostic equipment enables continuous tracking and improved treatment outcomes, particularly for the early detection of diseases like cancer.

• Growing aging population:

Nanomedicine and healthcare solutions are receiving more attention due to the ageing population and rising global life expectancy. Nanomedicine offers personalized medication delivery, improved diagnostics, and regenerative medicine techniques to meet the healthcare needs of the elderly and enhance their quality of life as the prevalence of age-related diseases rises. Despite differences in market data, nanomedicine's overall impact on addressing the challenges posed by an aging population remains significant.

• Government support and investments;

The business of nanomedicine thrives on government funding. World governments invest billions of dollars in research, infrastructure, and regulatory frameworks because they see its potential. Innovation is boosted by these projects, which enhance academic, business, and healthcare collaboration.

The nanomedicine market is set to expand at a constant pace in the forecast period.

The nanomedicine market is segmented by technology, application, end-user, product, and geography. Technology is further segmented into machine learning, deep learning, natural language processing, and other AI technologies. The product is further segmented into nanoparticles, nanosensors, nanodevices, etc.

North America has been at the forefront of the nanomedicine research and development market.

Due to significant investments in research facilities by pharmaceutical companies, and the government in major North American economies namely the United States and Canada have provided a positive outlook for the market growth of nanomedicine in the region. However, the regulatory frameworks may slow down the market growth, but favourable efforts to reduce growing chronic disease prevalence may bolster the market growth.

Recent Developments:

• In May 2023, One of the Janssen Pharmaceutical Companies owned by Johnson & Johnson, Janssen Biotech, Inc., today announced a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture, and market the next-generation therapies using chimeric antigen receptor (CAR) T cells to diagnose and treat B-cell cancers.

Nanomedicine Market Scope:

 

Report Metric	Details
Market Size Value in 2021	US$221.12 billion
Growth Rate	CAGR during the forecast period
Base Year	2021
Forecast Period	2023 – 2028
Forecast Unit (Value)	USD Billion
Segments Covered	Application End-User Type Deployment Geography
Companies Covered	IBM Corporation Microsoft Corporation Accenture PLC Change Healthcare Guardtime
Regions Covered	North America, South America, Europe, Middle East and Africa, Asia Pacific
Customization Scope	Free report customization with purchase

 

Segmentation

• BY APPLICATION
  • Drug Delivery
  • Regenerative Medicine
  • Diagnostic Imaging
  • Cancer Treatment
  • Infectious Disease Treatment
  • Others 
• BY TECHNOLOGY
  • Machine Learning
  • Deep Learning
  • Natural Language Processing (NLP)
  • Other AI Technologies       
• BY PRODUCT
  • Nanoparticles
  • Nanoparticles Therapeutics
  • Nanosensors
  • Nanodevices
  • Others 
• BY END-USER
  • Hospitals and Clinics
  • Research Institutes and Laboratories
  • Pharmaceutical Companies
  • Others 
• BY GEOGRAPHY
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain    
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Taiwan
    • Others

---

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2.  Research Process

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porters Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.1. Bargaining Power of Buyers

4.3.2. Threat of New Entrants

4.3.3. Threat of Substitutes

4.3.4. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. NANOMEDICINE MARKET BY APPLICATION

5.1. Introduction

5.2. Drug Delivery

5.3. Regenerative Medicine

5.4. Diagnostic Imaging

5.5. Cancer Treatment

5.6. Infectious Disease Treatment

5.7. Others  

6. NANOMEDICINE MARKET BY TECHNOLOGY

6.1. Introduction

6.2. Machine Learning

6.3. Deep Learning

6.4. Natural Language Processing (NLP)

6.5. Other AI Technologies        

7. NANOMEDICINE MARKET BY PRODUCT

7.1.  Introduction

7.2. Nanoparticles

7.3. Nanoparticles Therapeutics

7.4. Nanosensors

7.5. Nanodevices

7.6. Others  

8. NANOMEDICINE MARKET BY END-USER

8.1.  Introduction

8.2. Hospitals and Clinics

8.3. Research Institutes and Laboratories

8.4. Pharmaceutical Companies

8.5. Others  

9. NANOMEDICINE MARKET BY GEOGRAPHY

9.1. Introduction

9.2. North America

9.2.1. United States

9.2.2. Canada

9.2.3. Mexico

9.3. South America

9.3.1. Brazil

9.3.2. Argentina

9.3.3. Others

9.4. Europe

9.4.1. United Kingdom

9.4.2. Germany

9.4.3. France

9.4.4. Italy

9.4.5. Spain

9.4.6. Others

9.5. Middle East and Africa

9.5.1. Saudi Arabia

9.5.2. UAE

9.5.3. Others

9.6. Asia Pacific

9.6.1. Japan

9.6.2. China

9.6.3. India

9.6.4. South Korea

9.6.5. Indonesia 

9.6.6. Taiwan

9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

10.1. Major Players and Strategy Analysis

10.2.  Market Share Analysis

10.3. Mergers, Acquisitions, Agreements, and Collaborations

11. COMPANY PROFILES

11.1. Nanobiotix 

11.2. Microsoft Corporation

11.3. Alphabet Inc. (Google)

11.4. NVIDIA Corporation

11.5. Atomwise, Inc.

11.6. BenevolentAI

11.7. Exscientia Ltd.

11.8. Insilico Medicine

11.9. Cyclica Inc.

11.10. Cloud Pharmaceuticals, Inc.

Nanobiotix 

Microsoft Corporation

Alphabet Inc. (Google)

NVIDIA Corporation

Atomwise, Inc.

BenevolentAI

Exscientia Ltd.

Insilico Medicine

Cyclica Inc.

Cloud Pharmaceuticals, Inc.